When pharmacogenomics goes public

New Genetics and Society

Volumn 21, Issue 1, 2002, Pages 29-37

  Møldrup, Claus ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ETHICS; FEAR; GENETIC ANALYSIS; GENETIC MARKER; LITERATURE; PHARMACOGENOMICS; POLITICS; PRIORITY JOURNAL; PUBLIC HEALTH; PUBLIC OPINION; RISK ASSESSMENT; SCIENCE;

GOES;

EID: 18344378072     PISSN: 14636778     EISSN: None     Source Type: Journal    
DOI: 10.1080/14636770220122755     Document Type: Article

References (55)

1. Current and future applications of pharmacogenomics
2. Pharmacogenomics: It's not just pharmacogenetics
3. Altering human genes: Social, ethical, and legal implications
4. Patenting and human genes
5. The new genetics in clinical practice
6. Pharmacogenetics becomes pharmacogenomics: Wake up and get ready
7. Impact of genomics on drug discovery and clinical medicine
8. Pharmacogenomics: Translating functional genomics into rational therapeutics
9. Impact of pharmacogenetics on health care and health economics
10. Pharmacogenetics, race, and ethnicity: Social identities and individualized medical care
11. How will knowledge of the human genome affect drug therapy?
12. Ethics of population genomics research
13. Genetic discrimination and health insurance: An urgent need for reform
14. Ethical considerations in clinical pharmacogenomics research
15. Caught in the middle again: Professional ethical considerations in genetic testing for health risks
16. Opportunities abound in pharmacogenomics
17. Genetisk testning og deltagelse i kliniske afprovninger af laegemidler
18. From one stigma to another - Perceptions of younger women using SSRI antidepressants
19. Genetic discrimination: Perspectives of consumers
20. Pharmacogenomics a review of concepts and contents
21. The genome program's conscience
22. Getting the right drug into the right patient
23. Update on adjuvant chemotherapy for early breast cancer
24. The ethical, legal, and social implications research program at the National Human Genome Research Institute
25. Pharmacogenetics: The slow, the rapid, and the ultrarapid
26. Pharmacogenetics and adverse drug reactions
27. Ethical, social and legal implications of pharmacogenomics - A critical review
28. Farmakogenetikkens betydning for den primære sundhedssektor
29. Skræddersyede lægemidler til individuelle genomer
30. Risk of future drugs - A Delphi expert study
31. Methodological developments in medical technology assessment - The prospective approach
32. Taking it personally
33. Drug reactions, enzymes and biochemical genetics
34. Use of polymorphism analysis required ethical guidelines
35. Pharmacogenetics and pharmacogenomics: Why is this relevant to the clinical geneticist
36. Pharmacogenetics and public health: A good match
37. Putting the code to work: The promise of pharmacogenetics and pharmacogenomics
38. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer
39. A SNPshot: Pharmacogenetics and the future of drug therapy
40. Clinical trials in pharmacogenetics and pharmacogenomics: Methods and applications
41. Consent and privacy in pharmacogenetic testing
42. Pharmacogenetics and the practice of medicine
43. Pharmacogenetic; a disruptive technology for the next decade
44. The challenge of pharmacogenetics and pharmacogenomics
45. Who should know about our genetic makeup and why?
46. The sequence of the human genome
47. Initial sequencing and analysis of the human genome
48. Twin studies in pharmacogenetics
49. Moderne probleme der humangenetik
50. Pharmacogenomics: The next logical step
51. Who has the right to know the genetic constitution of a particular person